Reata Pharma (RETA) Appoints Steven W. Ryder to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Reata Announces the Appointment of Steven W. Ryder, M.D. to its Board of Directors
July 11, 2022 6:45 AM EDTPLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (Reata, the Company, or we), a clinical-stage biopharmaceutical company, today announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022.
We are thrilled to welcome Dr. Ryder to Reatas board, said Warren Huff, Reatas Chief Executive Officer. He is joining us at a critical point in Reatas development with our New Drug Application under review with the U.S. Food and Drug Administration for omaveloxolone for the treatment of patients with Friedreichs ataxia. His knowledge will be... More
